OGN
Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General · US
$13.78
+0.04%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
4.0x
EV/EBITDA
8.5x
Market Cap
$3.62B
MomentumView details →
1D Return
+0.04%
YTD Return
+92.12%
RSI (14)
75.1
ValuationView details →
P/E (Fwd)
4.0x
EV/EBITDA
8.5x
Market Cap
$3.62B
RSI (14)
75.1
MomentumView details →
1D Return
+0.04%
YTD Return
+92.12%
SummaryUpdated Jun 1, 2026
Organon & Co. (NYSE:OGN) is a global healthcare company that was spun off from Merck & Co. in 2021, focusing on women's health, biosimilars, and established pharmaceutical brands. Founded as an independent entity in 2020 and incorporated in Jersey City, New Jersey, the company went public in May 2021. Organon operates as a specialty pharmaceutical company with a diverse portfolio of prescription therapies sold in the United States and internationally, serving healthcare providers, patients, and health systems worldwide.
Similar companies
Latest newsMore news →
Sun Pharmaceutical Industries' proposed acquisition of Organon has been approved by shareholders.34d agoShareholders of Organon & Co. approved the merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting.43d agoSun Pharma announced it is buying American pharmaceutical company Organon in a deal valued at about $11.75 billion, including debt.62d ago